Literature DB >> 17684627

[Transient diabetes mellitus related to L-asparaginase therapy].

Crésio Alves1, Carina Chaves, Mabel Souza.   

Abstract

Treatment of hematological malignancies with L-asparaginase has been associated with diabetes mellitus in about 1-2% of patients. The concomitant use of steroids has an additional deleterious effect. In this article, we report the occurrence of diabetes in a 13 year-old girl treated with L-asparaginase and dexamethasone for acute lymphoblastic leukemia. The diabetes developed 120 days after the drug was started, requiring insulin therapy for 12 months. Anti-islet autoantibody was negative, and there were no laboratory findings suggestive of pancreatitis. The DM related do L-asparaginase therapy is insulinopenic and transient, resolving with suspension of the drug. The diagnosis of this type of diabetes is based on its temporal relationship with the L-asparaginase and in the exclusion of other known causes. There is no laboratory test capable of elucidating the diagnosis. Therefore, investigation to rule out type 1A DM, type 1B DM, insulin-resistant DM induced by corticotherapy and DM secondary to toxic pancreatitis is of utmost importance. The insulin therapy must be followed closely, since this is a transient form of diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684627     DOI: 10.1590/s0004-27302007000400020

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  2 in total

1.  Steroid induced diabetes mellitus in patients receiving prednisolone for haematological disorders.

Authors:  T R Kotila; T Olutogun; A Ipadeola
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

2.  Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients.

Authors:  Shan-Shan Suo; Chen-Ying Li; Yi Zhang; Jing-Han Wang; Yin-Jun Lou; Wen-Juan Yu; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.